Peptide record

TPDB24490

Antibacterial Anticancer Antiviral Toxicity standard
46 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB24490
Antibacterial Anticancer Antiviral Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia AI4AVP dbAMP 3.0 DRAVP 2.0
standard
No
A 46-aa standard-residue multi-activity (Antibacterial, Anticancer, Antiviral, and other sources) peptide sequence curated from Peptipedia, AI4AVP, dbAMP 3.0, and other sources, with an available 3D structural model.
Sequence
QKQIANQFNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQ
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C216H366N64O73
RCHMPWY
Q
5027.67
10.16
4
2
17
+2
1.73
-0.457
97.61
Mammalian: 0.8 hour Yeast: 10 min E.coli: >10 hour
0
0.00
22
Residue Composition
number
5
A
0
R
5
N
1
D
0
C
1
E
9
Q
1
G
0
H
3
I
5
L
4
K
0
M
1
F
0
P
3
S
5
T
0
W
0
Y
3
V
Amino Acid Distribution
A: 5 R: 0 N: 5 D: 1 C: 0 E: 1 Q: 9 G: 1 H: 0 I: 3 L: 5 K: 4 M: 0 F: 1 P: 0 S: 3 T: 5 W: 0 Y: 0 V: 3
Chemical Descriptors
46 reviewed residue count
C216H366N64O73 sequence-only estimate (linear, free termini)
5027.67 sequence-only estimate (linear, free termini)
10.16 sequence-only estimate (linear, free termini)
+2 sequence-only estimate (linear, free termini)
1.73 sequence-only estimate (linear, free termini)
-0.457 sequence-only estimate (linear, free termini)
Evidence Records 1 records
Evidence 1 Activity

Activity

0% Cytotoxicity
Toxicity
25 µM
Cytotoxic
0% Cytotoxicity | 25 | µM | target cell: Vero E6 cells

Target

Vero E6 cells

Source & Reference

NA
DBAASP
Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors. | Antiviral Res | 2009